Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2352W HIGH $6.51
Volume
4.54 M
Value Traded
16.45 M
Short % Float
9.58%
-10%Week
-13.2%1 Month
-16.38%3 Month
+33.07%6 Month
-21.76%5 Year
-95.64%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.10 B
EPS (TTM)
-0.08
P/E Ratio
-
Ent. Value
1.31 B
Total Shares
321.58 M
Float Shares
306.97 M
Insiders
4.53%
Institutions
54.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MNKD Catalyst Timeline
Dated clinical, regulatory and corporate events for MannKind Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for MannKind Corporation
620Total events
13Upcoming
128Tier-1 (high impact)
2013 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseTechnosphere/InsulinCorporate
MannKind and Rose Pharma enter worldwide licensing and collaboration agreement for ROSE-010 Technosphere in weight management
weight managementsource ↗
▲Product LaunchAfrezzaApprovedPost-Market
Launched pediatric indication of Afrezza
diabetes in children and adolescents ages 6 and oldersource ↗
▲Topline ReadoutMNKD-201Clinical Data
Positive topline data from INFLO-1 Phase 1b study
idiopathic pulmonary fibrosissource ↗
●Trial InitiationMNKD-201Trial
Global Phase 2 INFLO-2 study enrollment underway
idiopathic pulmonary fibrosissource ↗
▲Milestone PaymentMNKD-1501Corporate
Received $5 million payment from United Therapeutics
pulmonary arterial hypertensionsource ↗
●Trial CompletionAfrezzaApprovedTrial
Completion of Afrezza pediatric study INHALE-1
type 1 diabetes in youthsource ↗
▼Trial DiscontinuedMNKD-101DiscontinuedTrial
Discontinuation of ICoN-1 clinical study for MNKD-101
▲Breakthrough Therapy DesignationAfrezzaApprovedDesignation
Breakthrough T1D grant awarded for INHALE-1 ST
type 1 diabetes in youthsource ↗
▲Product LaunchFuroscixApprovedPost-Market
FUROSCIX ReadyFlow expected to be commercially available
edema in heart failure or chronic kidney diseasesource ↗
▲Topline ReadoutClinical Data
Positive topline results from INFLO-1 Phase 1b study of nintedanib DPI in IPF
idiopathic pulmonary fibrosissource ↗
▲Enrollment CompleteTrial
INFLO-1 enrollment completed with 27 patients
idiopathic pulmonary fibrosissource ↗
●Enrollment UpdateTrial
INFLO-2 Phase 2 study actively enrolling patients
idiopathic pulmonary fibrosissource ↗
▲Primary Endpoint MetClinical Data
INFLO-1 met primary objective of safety and tolerability
idiopathic pulmonary fibrosis (IPF)source ↗
●Trial InitiationTrial
Global Phase 2 INFLO-2 study actively enrolling
idiopathic pulmonary fibrosissource ↗
●Oral PresentationPresentation
Conference call and webcast to discuss INFLO-1 results
idiopathic pulmonary fibrosissource ↗
▲FDA ApprovalFuroscixApprovedFDA Decision
FDA approval of Furoscix ReadyFlow for edema in HF or CKD
edema in adults with heart failure or chronic kidney diseasesource ↗
▲FDA ApprovalFuroscixApprovedFDA Decision
FDA approval of FUROSCIX ReadyFlow autoinjector
edema in heart failure or chronic kidney diseasesource ↗
▲Breakthrough Therapy DesignationDesignation
Breakthrough T1D grant awarded to support INHALE-1ST trial of Afrezza
type 1 diabetessource ↗
▲Enrollment CompleteAfrezzaApprovedTrial
Completed enrollment of pilot phase of INHALE-1ST trial
type 1 diabetessource ↗
◆Poster PresentationAfrezzaApprovedPresentation
Poster: Subcutaneous Furosemide Use for Fluid Overload in Persons Living with Diabetes Mellitus
diabetessource ↗
◆Oral PresentationAfrezzaApprovedPresentation
Late-breaking comparative data vs. rapid-acting insulin analogs at ADA 2026
diabetessource ↗
◆Poster PresentationAfrezzaApprovedPresentation
Poster: Inhaled Technosphere Insulin Compared with Rapid-Acting Analog Insulin in Gestational Diabetes
gestational diabetessource ↗
◆Poster PresentationAfrezzaApprovedPresentation
Poster: Efficacy and Safety of Inhaled Technosphere Insulin vs. Rapid-Acting Analog in Youth with HbA1c ≤9.5%: Subgroup Analysis from INHALE-1
diabetessource ↗
▲Enrollment CompleteTrial
Completion of patient randomization in Phase 1b INFLO-1 study
idiopathic pulmonary fibrosissource ↗
▲First Patient DosedTrial
First patient enrolled in global Phase 2 INFLO-2 trial
idiopathic pulmonary fibrosissource ↗
▲FDA ApprovalAfrezzaApprovedFDA Decision
FDA approval of Afrezza for pediatric use
diabetes in children and adolescents ages 6 and oldersource ↗
▲Primary Endpoint MetAfrezzaApprovedClinical Data
Phase 3 INHALE-1 study results supported approval
type 1 and type 2 diabetes in children and adolescents aged 6 and oldersource ↗
◆PDUFA DateAfrezzaApprovedRegulatory Filing
PDUFA target action date for Afrezza pediatric sBLA
type 1 or type 2 diabetes in children and adolescents ages 4-17source ↗
▲Enrollment CompleteMNKD-201Trial
Completed enrollment of Cohort 1 in Phase 1b INFLO-1 trial
idiopathic pulmonary fibrosis (IPF)source ↗
▲Partnership / LicenseMNKD-1501Corporate
Collaboration with United Therapeutics for ralinepag DPI
pulmonary arterial hypertensionsource ↗
▲FDA ApprovalAfrezzaApprovedFDA Decision
FDA approved updated Afrezza label providing starting dose guidance
pediatric type 1 diabetessource ↗
▲Trial CompletionAfrezzaApprovedTrial
Completed pilot phase of INHALE-1st pediatric study
newly diagnosed type 1 diabetessource ↗
●Oral PresentationAfrezzaApprovedPresentation
New data presented from pediatric and adult studies of Afrezza
diabetessource ↗
▲FDA ApprovalAfrezzaApprovedFDA Decision
FDA approval for pediatric use (age 6 and older)
diabetes mellitus (pediatric)source ↗
▲Milestone PaymentCorporate
United Therapeutics made $5 million payment to MannKind in April 2026
▲First Patient DosedMNKD-201Trial
First patient enrolled in Phase 2 INFLO-2 trial of MNKD-201
idiopathic pulmonary fibrosis (IPF)source ↗
◆Trial InitiationMNKD-201Trial
First patient anticipated for INFLO-2 Phase 2 study
not specifiedsource ↗
◆Oral PresentationAfrezzaApprovedPresentation
Oral presentation: Refining Care of Type 1 Diabetes: Inhaled Insulin Use in Pediatrics – INHALE-1 Study
type 1 diabetessource ↗
◆Oral PresentationAfrezzaApprovedPresentation
Oral presentation: Inhaled Insulin Dosing & Post Prandial Glucose Excursions Across Multiple Studies
type 1 diabetessource ↗
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference fireside chat
◆Poster PresentationAfrezzaApprovedPresentation
Poster: Inhaled Technosphere Insulin Dosing in Youth with T1D
type 1 diabetessource ↗
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference fireside chat
Past FDA Catalysts and PDUFA Decisions
How MNKD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-24 | FUROSCIX ReadyFlow™ Autoinjector (SCP-111) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$202M
Pipeline Value
$901M
Commercial Value
Fair Value
Valuation Signal
2
Drugs Scored
0.6x
rNPV / MCap
Top 30%
Micro Cap(rank 198 of 658)
Percentile Rank
MannKind Corporation carries a moderate pipeline score (44/100), with $617M risk-adjusted pipeline value, led by Fursemide for administration in Heart Failure (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $393.6M x 2.3 = $901M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Afrezza | $74M | $67M | +10.7% |
| Furoscix | $61M | - | - |
| V Go | $14M | $18M | -20.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fursemide for administration Small moleculeCompletedNCT02329834 | Heart Failure | Phase 2 | COMPLETED | 23 | Oct 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every MNKD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| nintedanib DPI | idiopathic pulmonary fibrosis (IPF) | Phase 1b | 2026-07-29 | No serious adverse events; No drug-related gastrointestinal side effects (i.e., diarrhea, nausea, vomiting); No bronchospasm events; No treatment discontinuations or dose reductions; 90% of patients had no [60%] or mild [30%] cough; ~450 total inhalations administered in patients with IPFRead More | MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPFRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Binder Steven B.Director | Sell | -39,051 713,258 held | $3.29 | 09/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MNKD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0.6 % (50 %) | 28.12 M | 6.60 M | 11.86% ( 700.00 K) |
MNKD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MNKD ranks across every disease it competes in
Competitive Position is a premium feature
See how MNKD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMNKD News
MNKD▼ -5.3%on this news
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MannKind Corporation and Rose Pharma Inc. have entered a licensing agreement to develop ROSE-010, an inhaled GLP-1 receptor agonist aimed at weight management. MannKind will provide support through the completion of a Phase 1b clinical study and will receive equity and potential royalties. The collaboration seeks to address unmet needs in obesity treatment and irritable bowel syndrome.
Read more →MNKDMannKind to Present at Upcoming Investor Conferences
MannKind Corporation has announced its participation in two upcoming investor conferences. The management team will present at the Cantor Global Healthcare Conference on September 10, 2026, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts will be available on their website, along with recorded versions post-conference.
Read more →MNKD▼ -5.1%on this news
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation reported a strong financial performance for Q2 2026, with total revenues reaching $109.4 million, a 43% increase compared to the previous year. The company achieved significant milestones, including the FDA approval of the pediatric indication for Afrezza and the FUROSCIX ReadyFlow autoinjector. Positive Phase 1b data for nintedanib DPI supports ongoing development efforts.
Read more →MNKDMannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MannKind Corporation announced positive results from its Phase 1b INFLO-1 study, showing that nintedanib dry powder inhalation (DPI) is safe and well tolerated in patients with idiopathic pulmonary fibrosis (IPF). The study involved 27 patients and reported no serious adverse events or significant side effects. The company is now advancing to a Phase 2 trial, actively enrolling participants to further evaluate the treatment's efficacy.
Read more →MNKDMannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MannKind Corporation will announce its second quarter 2026 financial results on August 5, 2026. Following the report, a conference call will be held at 4:30 p.m. ET to discuss the results and provide a business update. The call will be accessible via the company's website, with a replay available for 90 days.
Read more →MNKD▲ +6.2%on this newsshared move
MannKind Announces $50 Million Private Placement
MannKind Corporation has announced a $50 million private placement to institutional investors, expected to close on July 24, 2026. The funds will primarily support a $45 million payment related to the recent FDA approval of Furoscix ReadyFlow™. The placement involves the sale of common stock and pre-funded warrants, with the securities not registered under the Securities Act.
Read more →MNKD▲ +6.2%on this newsshared move
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
MannKind Corporation has received FDA approval for Furoscix ReadyFlow, an autoinjector that delivers IV-equivalent furosemide for treating edema in adults with heart failure or chronic kidney disease. This innovative device allows for self-administration outside of hospital settings, potentially reducing emergency visits and hospitalizations. The therapy is expected to be commercially available by August 2026.
Read more →MNKDMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
MannKind Corporation has received a grant from Breakthrough T1D to support the INHALE-1ST clinical trial, which evaluates the use of Afrezza in pediatric patients newly diagnosed with type 1 diabetes. This study aims to assess the safety and efficacy of Afrezza combined with basal insulin in youth aged 10 to under 18. The collaboration emphasizes the importance of advancing inhaled insulin options for pediatric diabetes care.
Read more →MNKDData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
MannKind Corporation announced new clinical and real-world data on Afrezza at the ADA 2026 Scientific Sessions. The data highlights the safety, efficacy, and treatment satisfaction of inhaled insulin in pediatric patients and its potential use with automated insulin delivery systems. Recent findings support Afrezza as a viable alternative for managing diabetes in children and adolescents.
Read more →MNKDMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Corporation has announced significant milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the Phase 1b INFLO-1 study and the enrollment of the first patient in the Phase 2 INFLO-2 trial. Data from the INFLO-1 study is expected in Q3 2026, which will assess safety, tolerability, and pharmacokinetics. The Phase 2 trial aims to evaluate efficacy and safety across approximately 210 participants globally.
Read more →MNKD▲ +5.3%on this newsshared move
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Corporation has received FDA approval for Afrezza, the first inhaled mealtime insulin for children and adolescents aged 6 and older with diabetes. This innovative treatment allows for dosing at the start of meals, providing a flexible, needle-free option for managing diabetes. The approval is based on extensive clinical data, including the Phase 3 INHALE-1 study, and aims to enhance pediatric diabetes care.
Read more →MNKDMannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind Corporation announced a conference call to discuss the FDA's recent approval of Afrezza for children and adolescents aged 6 and older with diabetes. The call will feature CEO Michael Castagna and Senior VP Kevin Kaiserman. The event is scheduled for May 29, 2026, at 4:30 p.m. Eastern.
Read more →MNKDMannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza ) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MannKind Corporation is set to present new analyses on its inhaled insulin Afrezza at the ADA 2026 Scientific Sessions. The findings will explore Afrezza's use in pediatric patients, pregnant women, and its compatibility with automated insulin delivery systems. The data aims to support the upcoming FDA target action date of May 29, 2026, for Afrezza's use among children and adolescents living with diabetes. The company is optimistic about the potential approval, claiming it would bring the first needle-free insulin option to pediatric patients in over a century.
Read more →MNKDMannKind to Present at Jefferies Global Healthcare Conference
MannKind Corporation announced that its CEO, Michael Castagna, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3. The event will be accessible via a live audio webcast on the company's website, with recorded versions available for 90 days post-conference. MannKind is dedicated to developing treatments for chronic diseases.
Read more →MNKD▲ +24.5%on this news
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind Corporation has announced the development of a dry powder inhalation formulation of ralinepag in collaboration with United Therapeutics. The program aims to address pulmonary hypertension and fibrotic lung diseases. United Therapeutics has committed additional funding to support this initiative, which could yield significant milestone payments for MannKind. The formulation is expected to enter clinical studies soon.
Read more →MNKD▲ +24.5%on this newsshared move
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation reported its financial results for Q1 2026, showing total revenues of $90.2 million, a 15% increase from the previous year. The report highlighted advancements in various product lines, including upcoming PDUFA dates for Afrezza and Furoscix. However, the company faced challenges with rising operating expenses and lower gross margins as a result of new product integrations. CEO Michael Castagna emphasized that 2026 is poised to be a catalyst-rich year for the firm.
Read more →MNKDMannKind to Report First Quarter 2026 Financial Results on May 6, 2026
MannKind Corporation announced it will report its first quarter 2026 financial results on May 6, 2026, after the market closes. A webcast will follow at 4:30 PM Eastern Time to discuss the financial outcomes and provide a business update. The event can be accessed via MannKind's investor relations website, where a replay will also be available for 90 days post-call. The company focuses on developing treatments for cardiometabolic and orphan lung diseases, addressing significant unmet medical needs.
Read more →MNKDMannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
MannKind Corporation announced it will present new clinical data on Afrezza at the ATTD 2026 conference. The presentations will cover real-world dosing patterns and glucose management strategies for both adults and pediatric patients with type 1 diabetes. The FDA's review of Afrezza for children and adolescents is ongoing, with a target action date set for May 29, 2026.
Read more →MNKDMannKind Announces Settlement of Convertible Senior Notes
MannKind Corporation announced the successful settlement of $36.3 million in 2.50% convertible senior notes, all of which were converted prior to the maturity date. The settlement, completed on March 4, 2026, included $35.5 million in cash and the issuance of 569,023 shares of common stock. This step reflects MannKind's continued commitment to its financial obligations and its ongoing focus on addressing critical healthcare needs in cardiometabolic and orphan lung diseases.
Read more →MNKDMannKind to Participate in Upcoming Investor Conferences
MannKind Corporation will participate in two upcoming investor conferences in Miami. CEO Michael Castagna and CFO Chris Prentiss will engage in fireside chats and one-on-one meetings with investors. The conferences are scheduled for March 10 and March 11, 2026, and will be accessible via live audio webcasts on MannKind's website.
Read more →About MannKind Corporation
Headquarters1 CASPER STREET, DANBURY, CT, 06810
BIOPHARMAWATCH ELITE PLUS
Trade the next MNKD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime